Donate For Public and Patients Store Search

S009 - Therapeutic Hotline

Friday, March 1; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Utilize new therapeutics in treating patients with psoriasis, actinic keratoses, acne, rosacea, nail diseases, dyspigmentation, and hair disorders.
  • List new therapeutics for melanoma patients and recognize situations when they are required.
  • Identify and analyze newer research paradigms to treat common medical dermatological conditions with new cutting edge therapies

Description

This session will review new and emerging therapeutics for patients with psoriasis, melanoma, actinic keratoses, acne, rosacea, dyspigmentation, hair diseases, nail disorders, and non-melanoma skin cancer. The newest and what's hot in dermatology ranging from medical to cosmetic to surgical dermatology will be addressed, and in one 3 hour session, virtually the entire spectrum of dermatology will be covered. There will also be a discussion on sunscreens, and selecting the best photoprotection for UVA and UVB coverage.

Disclosures

  • Desai, Seemal R., MD: AbbVie – I(Grants/Research Funding); Almirall – C(Fees), SP(H); Cassiopea SpA – C(H); Dermavant Sciences – A(Fees); Dermira – C(H), I(Grants/Research Funding), SP(H); Dr. Reddy – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – A(Fees); Galderma Laboratories, LP – C(Fees); Menlo Therapeutics – C(H), I(Grants/Research Funding); Ortho Dermatologics – C(H), SP(H); Pfizer Inc. – SP(H); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Scientis – C(H), SP(H); SkinCeuticals LLC – C(H);
  • Grimes, Pearl E., MD: Allergan, Inc. – C(H), I(Grants/Research Funding); Clinuvel – I(H); Derm Tech International – I(NC); Incyte Corporation – I(Grants/Research Funding); Laseroptek USA – I(Grants/Research Funding); Procter & Gamble Company – C(H); Suneva Medical, Inc. – I(H); VT Technologies – I(Grants/Research Funding);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Avotres, Inc. – C(H); BirchBioMed – C(H); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Cara Therapeutics – C(H); Castle Biosciences, Inc – C(H); Celgene Corporation – I(Grants/Research Funding); Clinuvel – I(Grants/Research Funding); Corrona, Inc. – O(H); Dermavant Sciences – C(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Inozyme Pharma – C(H); Janssen Research & Development, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); LEO Pharma, US – I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Meiji Seika Pharma Co., Ltd – C(H); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Neuroderm LTD – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Rigel, Darrell S., MD: Aclaris Therapeutics, Inc. – C(H); Beiersdorf, Inc. – A(H); Castle Biosciences – A(H), I(Grants/Research Funding); Derm Tech International – A(H), C(H); Ferndale Laboratories, Inc. – C(H); Foamix – SH(SO); LEO Pharma, US – A(H); Myriad Genetics Inc – A(H); Novartis – A(H); Ortho Dermatologics – A(H); Pierre Fabre Dermo-Cosmétique US – A(H); SciBASE – C(H);
  • Shapiro, Jerry, MD: Aclaris Therapeutics Inc. – A(H); Allergan, Inc. – A(H); Applied Biology – C(H); Bayer Consumer Healthcare Pharmaceuticals – C(NC); Bioniz Therapeutics – A(Fees); Cassiopea SpA – A(NC); Incyte Corporation – C(NC); Johnson & Johnson Consumer Products Company – C(H); L'Oréal France – C(H); RegenLab – I(Grants/Research Funding); RepliCel Life Sciences – F(ST); Samumed, LLC – A(H);
  • Stein Gold, Linda F., MD: AbbVie – A(H); Actavis – SP(H); Allergan, Inc. – I(Grants/Research Funding); Aqua – A(H); Botanix Pharmaceuticals – C(H); Dermavant Sciences – A(H); Dermira – SP(H); Foamix – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); La Roche-Posay Laboratorie Pharmaceutique – A(H); Leo Pharma Inc. – I(Grants/Research Funding); LEO Pharma, US – A(H); Lilly ICOS LLC – A(H); Merz Pharmaceuticals, LLC – A(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – A(H), I(Grants/Research Funding); Promius Pharmaceuticals – A(H); Roche Laboratories – Independent Contractor(Fees), O(H); Sol-Gel Technologies – C(Grants/Research Funding); Taro Pharm – A(H), C(H); Topica – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H), I(Grants/Research Funding);
  • Sundaram, Hema A., MD: Allergan, Inc – C(H); Allergan, Inc. – SH(NC); Almirall – C(H); Biopelle, Inc. – C(H), I(Grants/Research Funding); Daewoong Pharmaceuticals – C(H); Eclipse Medical – C(EQ); Evolus, Inc. – I(Grants/Research Funding); Galderma USA – I(Grants/Research Funding); Hugel – C(H); IBSA – C(H); Menarini Group – C(H); Merz Aesthetics – C(H), I(Grants/Research Funding); Recros Medica – C(H), I(Grants/Research Funding); SkinCeuticals LLC – C(H); Strathspey Crown – SH(NC); Syneron, Inc. – C(H); TEOXANE Laboratories – C(H), I(Grants/Research Funding);
  • Tomecki, Kenneth J., MD: no financial relationships exist with commercial interests.
Schedule
Friday, March 1
1:00 PM
Dr. Desai / Welcome And Introduction
1:03 PM
Dr. Sundaram / What's New in Aesthetic Therapeutics
1:20 PM
Dr. Grimes / What's New in Vitiligo
1:40 PM
Dr. Desai / What's New in Hyperpigmentation
1:55 PM
Dr. Rigel / What’s New in Skin Cancer
2:15 PM
Dr. Sundaram, Dr. Grimes, Dr. Desai, and Dr. Rigel / Panel: Questions And Discussion
2:30 PM
Dr. Shapiro / What's New in Hair Disorders
2:50 PM
Dr. Stein Gold / What's New in Acne & Rosacea
3:10 PM
Dr. Lebwohl / What's New in Psoriasis
3:30 PM
Dr. Tomecki / What’s New in Infectious Disease
3:50 PM
Dr. Shapiro, Dr. Lebwohl, Dr. Tomecki, and Dr. Stein Gold / Panel: Questions And Discussion
Event Details
  • Date
    Friday, March 1
  • Time
    1:00 PM - 4:00 PM
  • Location
    Ballroom A
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Seemal R. Desai, MD, FAAD
Speakers
  • Darrell S. Rigel, MD, FAAD
  • Hema A. Sundaram, MD, FAAD
  • Jerry Shapiro, MD, FAAD
  • Kenneth J. Tomecki, MD, FAAD
  • Linda F. Stein Gold, MD, FAAD
  • Mark Lebwohl, MD, FAAD - Handout
  • Pearl E. Grimes, MD, FAAD